Anthony C Forster

US Patent:

6977150, Dec 20, 2005

Filed:

Jan 25, 2002

Appl. No.:

10/057783

Inventors:

Anthony C. Forster - Lexington MA, US
Stephen C. Blacklow - Lincoln MA, US

International Classification:

C12Q001/68
C12P021/00

US Classification:

435 6, 435 701, 435 691, 536 231, 530300

Abstract:

The present invention is a simplified, highly-purified, processive translation system that does not require the addition of translation factors EF-P, W, W2 or rescue. A new translation process offers new, potentially improved, routes to all peptides, proteins and peptidomimetics currently synthesized by alternative routes.

US Patent:

51680530, Dec 1, 1992

Filed:

Aug 17, 1990

Appl. No.:

7/568834

Inventors:

Sidney Altman - Hamden MA
Anthony C. Forster - Boston MA

Assignee:

Yale University - New Haven CT

International Classification:

C12P 1934
C12N 910
C12N 1500
A61K 3170

US Classification:

435 91

Abstract:

It has been discovered that it is possible to target any RNA molecule for cleavage by RNase P by forming a hybrid region consisting of a short sequence of base pairs followed by a terminal 3'- NCCA sequence. In the preferred embodiment, the region is formed by addition of an external guide sequence consisting of a nucleotide sequence complementary to the targeted site which includes a 3'-NCCA, wherein the sequence hybridizes to the targeted RNA to form a short sequence of double-stranded RNA under conditions promoting cleavage of the substrate at the nucleotide at the 5' side of the base-paired region by the RNase P or catalytically active equivalent thereof. Specificity is determined by the complementary sequence. The sequence is preferably ten to fifteen nucleotides in length and may contain non-complementary nucleotides to the extent this does not interfere with formation of several base pairs followed by a NCCA at the 3' end. These embodiments are particularly useful in the treatment of viral diseases and disorders associated with expression of specific proteins from mRNA.